Olaratumab
Phase 2Monoclonal antibody
Eli LillyOlaratumab is a monoclonal antibody that works as a Platelet-Derived Growth Factor Receptor Alpha Antagonist.[2] It is being investigated across 9 indications, with its most advanced program in Phase 2.[1]
Olaratumab is one of 270 small molecule programs targeting Leiomyosarcoma. It is currently in Phase 2.
9
Indications
19
Total Trials
0
Active Trials
269
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Olaratumab
Eli LillyPhase 2
Gemzar
GGynecologic Oncology Group
Preclinical
PORTRAZZA
Eli LillyPreclinical
Lenvima
EisaiPreclinical
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Soft Tissue Sarcoma9 trials
Show 6 more trials
OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Terminated·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT03698227·2 enrolled
Leiomyosarcoma1 trial
Children1 trial
Ovarian Cancer1 trial
6 more indications
Glioblastoma Multiforme1 trial
Solid Tumors1 trial
Non-Small Cell Lung Cancer1 trial
Gastrointestinal Stromal Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olaratumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]